Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology has announced promising research updates for its drug JSKN003, presented at the ESMO Congress 2025. The drug showed significant efficacy and a manageable safety profile in treating patients with primary platinum-refractory ovarian cancer (OC) and HER2+ metastatic colorectal cancer (CRC). The results indicate a potential new treatment option for these patient groups, which have limited existing therapies. The company is also progressing with a phase III study comparing JSKN003 to standard chemotherapy in patients with platinum-resistant ovarian cancer (PROC), which could further establish its position in the oncology market.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company specializes in creating bispecific antibodies and antibody-drug conjugates, targeting various types of cancers, with a particular emphasis on solid tumors.
Average Trading Volume: 4,202,481
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.02B
For a thorough assessment of 9966 stock, go to TipRanks’ Stock Analysis page.